Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2019

01-10-2019 | Breast Cancer | Preclinical study

β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer

Authors: Sasagu Kurozumi, Kyoichi Kaira, Hiroshi Matsumoto, Tomoko Hirakata, Takehiko Yokobori, Kenichi Inoue, Jun Horiguchi, Ayaka Katayama, Hiromi Koshi, Akira Shimizu, Tetsunari Oyama, Erica K. Sloan, Masafumi Kurosumi, Takaaki Fujii, Ken Shirabe

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Login to get access

Abstract

Purpose

Antitumor immunity plays an important role in the progression of breast cancer. β2-adrenergic receptor (β2AR) was found to regulate the antitumor immune response and breast cancer progression in preclinical studies. To understand the clinical role of β2AR in cancer progression, we investigated the clinicopathological and prognostic significance of β2AR expression in invasive breast cancer.

Methods

β2AR levels in breast tumors were evaluated by immunohistochemistry in a well-characterized patient cohort with long-term follow-up (n = 278). We evaluated the relationship of β2AR expression to patient survival and clinicopathological factors, including immune biomarkers such as tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression. Breast cancer-specific survival was compared between high- and low-β2AR expression groups.

Results

Although β2AR was not related to clinicopathological factors across the whole cohort, high β2AR was significantly related to PD-L1 negativity in estrogen receptor (ER)-negative patients. Tumors with high β2AR tended to have low TIL grade, and high β2AR was an independent prognostic factor for reduced survival in ER-negative patients.

Conclusions

β2AR is an independent poor prognostic factor in ER-negative breast cancer. The findings suggest that tumor β2AR regulates immune checkpoint activity, which may have therapeutic implications for patients with ER-negative breast cancer.
Appendix
Available only for authorised users
Literature
1.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
2.
Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281CrossRefPubMed
3.
Kurozumi S, Joseph C, Sonbul S et al (2018) Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. Breast Cancer Res Treat 172:61–68CrossRefPubMed
4.
Kurozumi S, Joseph C, Sonbul S et al (2018) Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. Breast Cancer Res Treat 170:525–533CrossRefPubMed
5.
Kurozumi S, Yamaguchi Y, Hayashi S et al (2016) Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. Cancer Med 5:1873–1882CrossRefPubMedPubMedCentral
6.
Baker JG, Hill SJ, Summers RJ (2011) Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci 32:227–234CrossRefPubMedPubMedCentral
7.
Renz BW, Takahashi R, Tanaka T et al (2018) β2 Adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell 33:75–90CrossRefPubMed
8.
Walker AK, Martelli D, Ziegler AI et al (2019) Circulating epinephrine is not required for chronic stress to enhance metastasis. Psychoneuroendocrinology 99:191–195CrossRefPubMed
9.
Masur K, Niggemann B, Zanker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61:2866–2869PubMed
10.
Chang A, Le CP, Walker AK et al (2016) β2-Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer. Brain Behav Immun 57:106–115CrossRefPubMedPubMedCentral
11.
Creed SJ, Le CP, Hassan M et al (2015) β2-Adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasion. Breast Cancer Res 17:145CrossRefPubMedPubMedCentral
12.
Botteri E, Munzone E, Rotmensz N et al (2013) Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat 140:567–575CrossRefPubMed
13.
14.
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X et al (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645–2652CrossRefPubMedPubMedCentral
15.
Palm D, Lang K, Niggemann B et al (2006) The norepinephrine-driven metastasis development of PC–3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118:2744–2749CrossRefPubMed
16.
Powe DG, Voss MJ, Habashy HO et al (2011) Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat 130:457–463CrossRefPubMed
17.
Hara MR, Kovacs JJ, Whalen EJ et al (2011) A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1. Nature 477:349–353CrossRefPubMedPubMedCentral
18.
Liu H, Wang C, Xie N et al (2018) Activation of adrenergic receptor β2 promotes tumor progression and epithelial mesenchymal transition in tongue squamous cell carcinoma. Int J Mol Med 41:147–154PubMed
19.
Sanders VM (2012) The beta2-adrenergic receptor on T and B lymphocytes: do we understand it yet? Brain Behav Immun 26:195–200CrossRefPubMed
20.
Qiao G, Bucsek MJ, Winder NM et al (2019) β-Adrenergic signaling blocks murine CD8 + T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress. Cancer Immunol Immunother 68:11–22CrossRefPubMed
21.
Nissen MD, Sloan EK, Mattarollo SR (2018) β-Adrenergic signaling impairs antitumor CD8 + T-cell responses to B-cell lymphoma immunotherapy. Cancer Immunol Res 6:98–109CrossRefPubMed
22.
Kurozumi S, Matsumoto H, Kurosumi M et al (2019) Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett 17:2647–2656PubMedPubMedCentral
23.
Darvin P, Toor SM, Sasidharan Nair V et al (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50:165CrossRefPubMedCentral
24.
Kurozumi S, Matsumoto H, Hayashi Y et al (2017) Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer 17:354CrossRefPubMedPubMedCentral
25.
Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259–271CrossRefPubMed
26.
Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920CrossRefPubMedPubMedCentral
27.
Kaira K, Kamiyoshihara M, Kawashima O et al (2019) Prognostic impact of β2 adrenergic receptor expression in surgically resected pulmonary pleomorphic carcinoma. Anticancer Res 39:395–403CrossRefPubMed
28.
Yazawa T, Kaira K, Shimizu K et al (2016) Prognostic significance of β2-adrenergic receptor expression in non-small cell lung cancer. Am J Transl Res 8:5059–5070PubMedPubMedCentral
29.
Takahashi K, Kaira K, Shimizu A et al (2016) Clinical significance of β2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. Tumour Biol 37:13885–13892CrossRefPubMed
30.
Shimizu A, Kaira K, Mori K et al (2016) Prognostic significance of β2-adrenergic receptor expression in malignant melanoma. Tumour Biol 37:5971–5978CrossRefPubMed
31.
Zhang ZF, Feng XS, Chen H et al (2016) Prognostic significance of synergistic hexokinase-2 and beta2-adrenergic receptor expression in human hepatocelluar carcinoma after curative resection. BMC Gastroenterol 16:57CrossRefPubMedPubMedCentral
32.
Kurozumi S, Fujii T, Matsumoto H et al (2017) Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol 50:185–194CrossRefPubMed
33.
Kurozumi S, Inoue K, Matsumoto H et al (2019) Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. Sci Rep 9:1583CrossRefPubMedPubMedCentral
34.
Bucsek MJ, Qiao G, MacDonald CR et al (2017) β-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy. Cancer Res 77:5639–5651CrossRefPubMedPubMedCentral
35.
Estrada LD, Ağaç D, Farrar JD (2016) Sympathetic neural signaling via the β2-adrenergic receptor suppresses T-cell receptor-mediated human and mouse CD8(+) T-cell effector function. Eur J Immunol 46:1948–1958CrossRefPubMedPubMedCentral
36.
Qin JF, Jin FJ, Li N et al (2015) Adrenergic receptor β2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. BMB Rep 48:295–300CrossRefPubMedPubMedCentral
37.
Sloan EK, Priceman SJ, Cox BF et al (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70:7042–7052CrossRefPubMedPubMedCentral
38.
Wu H, Chen J, Song S et al (2016) β2-Adrenoceptor signaling reduction in dendritic cells is involved in the inflammatory response in adjuvant-induced arthritic rats. Sci Rep 6:24548CrossRefPubMedPubMedCentral
39.
Denkert C, von Minckwitz G, Darb-Esfahani S et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19:40–50CrossRefPubMed
40.
Rody A, Holtrich U, Pusztai L et al (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11:R15CrossRefPubMedPubMedCentral
41.
Watanabe T, Hida AI, Inoue N et al (2018) Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. Breast Cancer Res Treat 168:135–145CrossRefPubMed
42.
Biswas SK (2015) Metabolic reprogramming of immune cells in cancer progression. Immunity 43:435–449CrossRefPubMed
43.
44.
Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N (2018) CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci 75:689–713CrossRefPubMed
45.
Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121CrossRefPubMed
46.
Metadata
Title
β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer
Authors
Sasagu Kurozumi
Kyoichi Kaira
Hiroshi Matsumoto
Tomoko Hirakata
Takehiko Yokobori
Kenichi Inoue
Jun Horiguchi
Ayaka Katayama
Hiromi Koshi
Akira Shimizu
Tetsunari Oyama
Erica K. Sloan
Masafumi Kurosumi
Takaaki Fujii
Ken Shirabe
Publication date
01-10-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05341-6

Other articles of this Issue 3/2019

Breast Cancer Research and Treatment 3/2019 Go to the issue

Review

Social determinants of breast cancer risk, stage, and survival

Letter to the Editor

RE.: Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer

Epidemiology

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers

Epidemiology

A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy

Epidemiology

Mammographic screening in male patients at high risk for breast cancer: is it worth it?

Clinical trial

PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits